Company
Every investor coverage indicates participated in a round Institute for Molecular Bioscience raised.
Companies Institute for Molecular Bioscience acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Glenn King | Professorial Research Fellow | SmartCompany |
Stories naming Institute for Molecular Bioscience. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon BioCatalyst has named Peter Beattie its chair as Bill Ferris retires, with Andrew Nash joining the board and Ross King becoming deputy; manager Brandon Capital's newly raised $439 million fund was noted.